Leerink Partnrs Issues Pessimistic Outlook for EW Earnings

Edwards Lifesciences Co. (NYSE:EW) – Equities researchers at Leerink Partnrs dropped their Q3 2025 earnings estimates for Edwards Lifesciences in a note issued to investors on Wednesday, December 4th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will post earnings per share of $0.60 for the quarter, down from their prior estimate of $0.62. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q4 2025 earnings at $0.61 EPS, FY2025 earnings at $2.43 EPS and FY2026 earnings at $2.84 EPS.

Other equities analysts have also issued reports about the stock. Wells Fargo & Company lowered their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Truist Financial restated a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. Finally, Piper Sandler lowered their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and an average target price of $78.35.

Edwards Lifesciences Stock Performance

Shares of EW opened at $73.41 on Monday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $43.29 billion, a PE ratio of 10.59, a price-to-earnings-growth ratio of 3.52 and a beta of 1.12. The company’s 50 day simple moving average is $68.75 and its 200-day simple moving average is $74.29. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter last year, the company earned $0.59 earnings per share. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently modified their holdings of the company. Franklin Resources Inc. boosted its holdings in Edwards Lifesciences by 2.3% in the 3rd quarter. Franklin Resources Inc. now owns 1,196,059 shares of the medical research company’s stock worth $83,282,000 after acquiring an additional 27,193 shares during the period. Peapack Gladstone Financial Corp raised its position in shares of Edwards Lifesciences by 108.0% in the 3rd quarter. Peapack Gladstone Financial Corp now owns 293,758 shares of the medical research company’s stock valued at $19,385,000 after purchasing an additional 152,539 shares in the last quarter. Tidal Investments LLC raised its position in shares of Edwards Lifesciences by 0.7% in the 3rd quarter. Tidal Investments LLC now owns 39,532 shares of the medical research company’s stock valued at $2,609,000 after purchasing an additional 275 shares in the last quarter. Destination Wealth Management raised its position in shares of Edwards Lifesciences by 2.8% in the 3rd quarter. Destination Wealth Management now owns 7,012 shares of the medical research company’s stock valued at $463,000 after purchasing an additional 193 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB raised its position in shares of Edwards Lifesciences by 147.0% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 9,106 shares of the medical research company’s stock valued at $601,000 after purchasing an additional 5,420 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 35,000 shares of company stock valued at $2,323,150 in the last 90 days. 1.27% of the stock is currently owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.